Marianne Bjørdal

Marianne Bjørdal is a Monaco-based General Partner at 3B Future Health Ventures, where she specializes in early-stage healthcare investments targeting novel oncology treatments and rare diseases. She brings over 15 years of combined experience in scientific research and venture capital, having joined the firm in 2018 before her promotion to partner in 2022. Bjørdal currently serves on the boards of biotechnology companies including Epsilogen Ltd, Sibylla Biotech, GenEp Inc, and NeoPhore Ltd, which she joined following its £15.2 million financing round. Previously, she worked as a researcher at the French National Centre for Scientific Research and held a board seat at Gain Therapeutics Inc. She holds a PhD in Molecular and Cellular Biology from the University of Nice and an MBA from IAE Nice, and won the 2014 AXA Prize from the French Academy of Science.